Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR Mutations”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Ended earlyNCT03054038
What this trial is testing

Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Carcinoma
Vanderbilt-Ingram Cancer Center 22
Testing effectiveness (Phase 2)Study completedNCT01372384
What this trial is testing

Tarceva (Erlotinib) in Patients With Locally Advanced, Metastatic or Recurrent Non-Small Cell Cancer Who Present Epidermal Growth Factor Receptor Mutations

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 6
Large-scale testing (Phase 3)Not Yet RecruitingNCT04772287
What this trial is testing

Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)

Who this might be right for
Non Small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China 341
Testing effectiveness (Phase 2)UnknownNCT01955421
What this trial is testing

Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc

Who this might be right for
Advanced Stage Non Small Cell Lung Cancer
Sun Yat-sen University 224
Testing effectiveness (Phase 2)Looking for participantsNCT07079475
What this trial is testing

Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)

Who this might be right for
Non-Small Cell Lung Cancer
Dizal Pharmaceuticals 220
Not applicableStudy completedNCT01074177
What this trial is testing

Understanding Mechanisms of Acquired Resistance to BIBW2992

Who this might be right for
Non-small Cell Lung CancerEGFR Mutations
Massachusetts General Hospital 24
Testing effectiveness (Phase 2)Looking for participantsNCT06947811
What this trial is testing

Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS Mutations

Who this might be right for
EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 Inhibitor
Sun Yat-sen University 71
Not applicableNot Yet RecruitingNCT07714304
What this trial is testing

JS212 in Combination With JS111 as First-Line Treatment in EGFR-Mutant Advanced NSCLC

Who this might be right for
NSCLC Harboring EGFR Mutations
Huan Zhou 20
Not applicableStudy completedNCT03137264
What this trial is testing

Resistance & Activating Mutations Diagnosed Among NSCLC Community Dwelling EGFR Mutation Positive Patients

Who this might be right for
Non-small Cell Lung Cancer
AstraZeneca 44
Testing effectiveness (Phase 2)Study completedNCT02976116
What this trial is testing

A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer

Who this might be right for
NSCLC
Hutchison Medipharma Limited 50
Early research (Phase 1)Not Yet RecruitingNCT06015568
What this trial is testing

Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation

Who this might be right for
Non-Small Cell Lung Cancer、EGFR Sensitive Mutation
Betta Pharmaceuticals Co., Ltd. 172
Large-scale testing (Phase 3)UnknownNCT03856697
What this trial is testing

Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR Mutation

Who this might be right for
Advanced Non-small Cell Lung Cancer
Hangzhou ACEA Pharmaceutical Research Co., Ltd. 406
Testing effectiveness (Phase 2)Ended earlyNCT02949843
What this trial is testing

Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations

Who this might be right for
EGFR Activating MutationRecurrent Non-Small Cell Lung CarcinomaStage IV Non-Small Cell Lung Cancer
Wake Forest University Health Sciences 19
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07709585
What this trial is testing

Befotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated NSCLC Patients

Who this might be right for
Advanced Non-small Cell Lung Cancer (NSCLC)EGFR Exon 19 Deletion MutationEGFR Exon 21 Mutation+1 more
Guangzhou University of Traditional Chinese Medicine 124
Large-scale testing (Phase 3)UnknownNCT04028778
What this trial is testing

Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC

Who this might be right for
Lung Cancer, Nonsmall Cell
Sun Yat-sen University 310
Large-scale testing (Phase 3)UnknownNCT04500717
What this trial is testing

Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Tumor Suppressor Gene Mutation

Who this might be right for
Non Small Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 460
Testing effectiveness (Phase 2)UnknownNCT02407366
What this trial is testing

Icotinib With Concurrent Radiotherapy vs. Chemoradiotherapy in Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
People's Hospital of Guangxi Zhuang Autonomous Region 80
Early research (Phase 1)Not Yet RecruitingNCT04933422
What this trial is testing

CM93 Treatment in Subjects With Epidermal Growth Factor Receptor (EGFR)-Modified Recurrent Glioblastoma (rGBM)

Who this might be right for
Glioblastoma
Crimson Biopharm Inc. 72
Testing effectiveness (Phase 2)Ended earlyNCT05215951
What this trial is testing

Osimertinib Plus Chemotherapy in Uncommon EGFRm NSCLC

Who this might be right for
Lung Cancer
AstraZeneca 4
Testing effectiveness (Phase 2)Active Not RecruitingNCT05466149
What this trial is testing

Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion

Who this might be right for
NSCLC
Allist Pharmaceuticals, Inc. 100
Next Page